CDK4/6抑制剂联合内分泌治疗对高风险侵袭性HR+/HER2-早期乳腺癌辅助治疗的疗效与安全性：一项全面的随机临床试验Meta分析
The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
正在获取期刊数据...
发表日期:2024 Dec
作者:
DOI:10.1016/j.breast.2024.103815
摘要
AI正在翻译并加载中文摘要...